Recent research from the National Library of Medicine highlights significant barriers to effective lung cancer screening. These include socioeconomic factors, limited access to screening technologies, and patient awareness. Understanding these obstacles is crucial for improving early diagnosis and treatment.
Cizzle Bio, Inc. is dedicated to addressing these challenges with the CIZ1B biomarker test, making screening more accessible and effective.
For a deeper dive into the findings and their implications, read the full article on Cizzle Bio, Inc.’s website: Overcoming Barriers in Lung Cancer Screening